Barron takes on business development role

Eurofins AvTech Laboratories has appointed Michael Barron as director of business development.

Eurofins AvTech Laboratories, a US analytical contract research organisation (CRO), has appointed Michael Barron as director of business development.

Barron has previously worked for Catalent Pharma Solutions, Cardinal Health, and other leading contract drug development and analytical service companies.

AvTech offers analytical support for all stages of drug discovery and development from early ADME studies of drug candidates to stability and release testing of the finished product. The company places particular emphasis on the development, validation, and routine performance of GMP and GLP compliant methods.




You may also like

Research & Development

BioGenes and Eurofins Munich form HCP analysis partnership

BioGenes specialises in highly sophisticated and customized antibody and immunoassay development
Research & Development

Merck Millipore to sell Discovery and Development Solutions Business to Eurofins

DDS provides bioanalytical testing and early stage discovery services to the biopharmaceutical market
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing

Degasser for volatile and aggressive solvents

Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Subscribe now